Welcome to our dedicated page for MDNA news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on MDNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MDNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MDNA's position in the market.
Medicenna Therapeutics (NASDAQ: MDNA) presented preclinical data on its bispecific IL-2/IL-13 Superkine platform at the ENA Symposium. The data suggest that MDNA11, a long-acting IL-2 Superkine, enhances anti-tumor CD8+ T cell activation while inhibiting pro-tumor signaling. The results indicate MDNA11's best-in-class potential, showing efficacy in multiple tumor models and no significant adverse effects in non-human primates. Medicenna plans to declare a lead candidate and initiate a Phase 1 clinical trial with MDNA11 in mid-2021.
Medicenna Therapeutics (NASDAQ: MDNA) presented updated clinical data for MDNA55 at the 36th Annual EORTC-NCI-AACR Symposium. The Phase 2b trial for recurrent glioblastoma (rGBM) showed a significant increase in 12-month progression-free survival (27% vs. 2-10%) and two-year survival (20% vs. 5-10%). A combination with low-dose bevacizumab yielded a median overall survival of 21.8 months. The FDA's support for an external control in trials may expedite MDNA55's development in addressing rGBM, emphasizing the urgent need for effective treatments.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced two abstracts for the EORTC-NCI-AACR Virtual Scientific Program on October 24-25, 2020. One abstract focuses on long-term survival data from the MDNA55-05 trial, presented by Dr. John Sampson, while the second presents pre-clinical data on MDNA11 and novel bi-specific IL-13 superkines, led by Dr. Minh To. The presentations will be available online starting October 24, 2020. Medicenna aims to revolutionize cancer treatment with its innovative immunotherapies.
Medicenna Therapeutics announced the presentation of two abstracts at the EORTC-NCI-AACR Virtual Scientific Program, scheduled for October 24-25, 2020. The first abstract discusses long-term survival results from the MDNA55-05 trial in recurrent glioblastoma multiforme, presented by Dr. John Sampson. The second abstract features updated pre-clinical data on MDNA11 and novel bi-specific IL-13 superkines, presented by Dr. Minh To. Both presentations will be available for on-demand viewing at Medicenna’s website after the event.
Medicenna has received FDA approval for a hybrid registration trial for MDNA55, targeting recurrent glioblastoma (rGBM). This innovative design allows two-thirds of the control arm to utilize matched external controls, which sets a new precedent for rGBM clinical trials. The aim is to reduce enrollment requirements, lower trial costs, and expedite regulatory approval timelines. The trial will evaluate overall survival data while minimizing patients randomized to standard of care treatments. Prominent medical professionals express optimism about the trial’s potential impact on patient outcomes.
Medicenna Therapeutics (NASDAQ: MDNA) has received FDA approval for a hybrid registration trial design for its MDNA55 treatment targeting recurrent glioblastoma (rGBM). This innovative approach will use matched external controls for two-thirds of the control arm, reducing participant enrollment and trial costs while expediting regulatory approval. The design aims to generate robust overall survival data, potentially setting a new precedent for oncology trials. With previous promising results, the company looks to advance its partnership strategy for future development.
Medicenna Therapeutics Corp. has received approval to list its common shares on The Nasdaq Capital Market, effective August 24, 2020, while retaining its listing on the Toronto Stock Exchange. This strategic move aims to enhance visibility, liquidity, and shareholder value. Medicenna's candidates, like MDNA11, a long-acting IL-2 Superkine, are progressing towards clinical trials. Notably, MDNA55 has completed a Phase 2b trial for a fatal brain cancer, showing promising efficacy and receiving FDA designations.